The Coronavirus Aid, Relief, and Economic Security (CARES) Act encourages charitable giving by increasing tax incentives for individuals and corporations. We want to make sure that anyone who supports us […]
CureDuchenne is pleased to share the news that Edgewise Therapeutics is starting a Phase 1 clinical trial to assess the safety, tolerability, and appropriate dose of their experimental therapeutic aimed […]
– EDG-5506 is a novel, oral, small molecule drug candidate with the potential to promote muscle function in patients with muscular dystrophy – Boulder, Colo., (November 11, 2020) – Edgewise […]
November 9, 2020 Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021Dosing in three new clinical trials with novel compounds […]
CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]
